Pembrolizumab–niraparib response in ovarian cancer identified by novel markers

Researchers at Dana-Farber Cancer Institute (MA, USA) have identified two key markers that may be capable of predicting the response of ovarian cancer patients to a combination of pembrolizumab–niraparib. Published this week in Nature Communications, the study could result in earlier targeted treatment of ovarian cancer.Clinical trials have previously shown that a combination of PARP and immune checkpoint inhibition can cause complete or limited remission in ovarian tumors. However, before now it has not been possible to detect which patients will benefit from such treatment, resulting in delayed access to effective therapies. Checkpoint inhibitors have proven incredibly effective in other...